Anavip
{{Short description|North American rattlesnake antivenin}}
{{cs1 config|name-list-style=vanc|display-authors=6}}
{{Infobox drug
| drug_name =
| INN =
| type =
| image =
| alt =
| caption =
| pronounce =
| tradename = Anavip
| Drugs.com =
| MedlinePlus =
| pregnancy_AU =
| pregnancy_AU_comment =
| pregnancy_category=
| routes_of_administration =
| ATCvet =
| ATC_prefix =
| ATC_suffix =
| legal_AU =
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA =
| legal_CA_comment =
| legal_DE =
| legal_DE_comment =
| legal_NZ =
| legal_NZ_comment =
| legal_UK =
| legal_UK_comment =
| legal_US =
| legal_US_comment =
| legal_EU =
| legal_EU_comment =
| legal_UN =
| legal_UN_comment =
| legal_status =
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action=
| excretion =
| synonyms = {{bulletedlist|Crotalidae immune F(ab')2 (equine)|Viper antivenom}}
| CAS_number =
| PubChemSubstance = 482023934
| UNII = 92VV7G83ED
| DrugBank = DB14114
| IUPAC_name =
| chemical_formula =
| molecular_weight =
}}
Anavip (stylized as ANAVIP) is the trade name of a snake antivenin indicated for the management of adult and pediatric patients with North American rattlesnake envenomation.{{cite journal | vauthors = Cocchio C, Johnson J, Clifton S | title = Review of North American pit viper antivenoms | journal = American Journal of Health-System Pharmacy | volume = 77 | issue = 3 | pages = 175–187 | date = January 2020 | pmid = 31974558 | doi = 10.1093/ajhp/zxz278 }}{{cite web |title=Marketing authorization with orphan designation - USA |url=https://www.orpha.net/consor/cgi-bin/Drugs_Search.php?lng=EN&data_id=116759&search=Drugs_Search_Simple&data_type=Status&Typ=Med |website=orpha.net |publisher=orphanet |access-date=19 August 2020}}{{Cite web|date=|title=Highlights of Prescribing Information|url=https://www.fda.gov/media/92139/download|archive-url=https://web.archive.org/web/20190929163847/https://www.fda.gov/media/92139/download|url-status=dead|archive-date=September 29, 2019|access-date=|website=U.S. Food & Drug Administration}} As defined by the FDA, the proper name is crotalidae immune F(ab')2 (equine).{{Cite journal|last=Research|first=Center for Biologics Evaluation and|date=2019-10-02|title=ANAVIP|url=https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/anavip|journal=FDA|language=en}} It is manufactured by Instituto Bioclon for Rare Disease Therapeutics in the United States.
Anavip is a divalent fragment antigen-binding protein, F(ab')2, derived from the blood of horses immunized with the venom of the snakes Bothrops asper and Crotalus durissus. The product is produced by pepsin digestion of horse blood plasma then purified resulting in a preparation containing >85% F(ab')2.{{cite web |last1=Laboratorios Silanes S.A. de C.V. |title=Highlights of Prescribing Information |url=https://www.anavip-us.com/resources/Package_Insert.pdf |website=Package_Insert |access-date=18 August 2020}}